DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Valued at a market cap of $27.5 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that ...

If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...

Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists 1. The new system will be available shortly. Dexcom ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

DexCom (NASDAQ:DXCM) is gearing up to announce its quarterly earnings on Thursday, 2026-02-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists 1. The new system will be available shortly. Dexcom ...